Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer

Fang, Cheng; Guo, Zhongqiang; Chen, Xiaoyan; Liu, Tong-Zu; Zeng, Xian‐Tao; Wang, Xinghuan

doi:10.1097/md.0000000000006791

Cited by 9 publications

(9 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After reading the full texts, 7 articles were excluded to duplicates (n = 5), review (n = 1), or lack of the relevant date (n = 1). Finally, a total of 33 case-control studies from 27 publications [ 14 , 22 , 23 , 30 – 53 ] which met our inclusion criteria, including 7276 cases and 9667controls. The main characteristics of each study identified are listed in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…Briefly, 12 case-control studies were performed in Asians, [ 22 , 23 , 36 – 38 , 40 , 41 , 44 , 45 , 50 , 52 , 53 ] 12 in Caucasians, [ 14 , 31 – 36 , 39 , 42 , 46 , 47 , 51 ] 5 in Mixed. [ 30 , 36 , 43 , 48 , 49 ] As for study design, there were 2 FB, [ 30 , 31 ] 14 PB, [ 14 , 23 , 32 , 33 , 36 , 37 , 39 , 41 – 45 , 48 , 50 , 53 ] and 11 HB. [ 22 , 34 , 35 , 38 , 40 , 43 , 46 , 47 , 49 , 51 , 52 ] Eleven studies described the specific location of CRC.…”

Section: Resultsmentioning

confidence: 99%

“…Cancer is a genetic and cell-cycle disease, its occurrence and development involve a multistep and polygenic process. [ 14 ] CyclinD1 (CCND1) is a key cell cycle regulatory protein, and its expression and cellular localization is often transformed in human tumor cells. CCND1 is the gate keeping protein that charges regulating the transition through the restriction point in the G1 phase to S phase of the cell cycle.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The association between CCND1 G870A polymorphism and colorectal cancer risk

Xie

Zhao²,

Zou³

et al. 2017

Medicine

View full text Add to dashboard Cite

Background:CyclinD1 (CCND1) is a key cell cycle regulatory protein. A large number of epidemiological studies have assessed the potential correlation between the CCND1 G870A polymorphism and the risk of colorectal cancer (CRC), but their findings have been inconsistent. To obtain a more precise understanding of the association between the G870A polymorphism in the CCND1 gene and the CRC risk, we conducted a more comprehensive meta-analysis.Methodology:We searched PubMed, Ovid, Springer, Weipu, China National Knowledge Infrastructure (CNKI), and Wanfang databases, covering all publications (the last search was updated on January 10, 2017). The pooled odds ratios (ORs) with 95% confidence intervals (CIs) were derived from a fixed effect or random effect model. Statistical analyses were performed using Review Manager 5.3 and STATA 10.0 software.Results:A total of 7276 CRC patients and 9667 controls from 27 publications were included in this meta-analysis. We found that compared with GG homozygote genetic model, AA, AG, AA + AG genetic models of the CCND1 G870A polymorphism were significantly associated with overall CRC risk (AA homozygote genetic model: OR = 1.28, 95% CI = 1.10–1.49; AG heterozygote genetic model: OR = 1.15, 95% CI = 1.06–1.25; AA homozygote + AG heterozygote genetic model: OR = 1.19, 95% CI = 1.07–1.33). Subgroup analyses by ethnicity and cancer location showed that A carriers were consistently associated with a significantly increased risk of CRC in all subsets of participants (Asian and Caucasian; colon cancer and rectal cancer). When stratified by study design, we found a significant association in hospital-based studies (HB), but no significant associations were found in either population-based studies (PB) or family-based studies (FB). According to subgroup analysis by cancer type, the risk of sporadic colorectal cancer (sCRC) and hereditary nonpolyposis colorectal cancer (HNPCC) were not correlated with the CCND1 G870A polymorphism, except AG (AG vs GG: OR = 1.30, 95% CI = 1.11–1.53).Conclusions:This meta-analysis suggests that the CCND1 G870A polymorphism is associated with an increased risk of CRC, especially that A carriers may be a major risk factor for CRC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The association between CCND1 G870A polymorphism and colorectal cancer risk

Xie

Zhao²,

Zou³

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…Another amino acid substitution at the same position (p.Ala49Thr) was present in a hemizygous state in the father and in a heterozygous state in the healthy sibling with apparently no effect on normal sexual development. This variant was previously described in association with hypospadias [19][20][21] and prostate cancer, although with inconsistent findings [22,23].…”

Section: A B Discussionmentioning

confidence: 82%

Novel genotype in two siblings with 5-α-reductase 2 deficiency: Different clinical course due to the time of diagnosis

Kočova

Plaseska-Karanfilska

Noveski

et al. 2019

Balkan Journal of Medical Genetics

View full text Add to dashboard Cite

Steroid 5-α-reductase-2 (5-ARD) deficiency is a result of mutations of the SRD5A2 gene. It causes the disorder of sexual differentiation (DSD) in 46,XY individuals with a variable genital phenotype. We present two siblings with female external genitalia at birth and bilateral inguinal testes, raised as females. These are the first molecularly characterized patients from the Republic of North Macedonia (RN Macedonia) with a different clinical course due to the time of the diagnosis. Diagnosis of Patient 1 was based upon the detection of bilateral inguinal testes and testosterone/dihidrotestosterone ratio. Sex reversal was initiated by testes removal at the age of 20 months. Breast implantation and vaginoplasty were performed in adolescence and the girl is comfortable with the female sex. Her sibling, Patient 2, raised as a girl, was clinically assessed at 11.5 years due to the growth of phalus, deep voice and Adam’s apple enlargement. No change of gender was accepted. Complex molecular analysis including multiplex quantitative fluorescent polymerase chain reaction (PCR) screening for sex chromosome aneuploidies and SRY presence, Sanger sequencing combined with multiplex ligation-dependent probe amplification (MLPA), microarray-based comparative genomic hybridization (aCGH), and real-time PCR analysis for detection of exon copy number changes confirmed a novel c.146C>A (p.Ala49Asp) point mutation in the first exon inherited from the mother, and complete deletion of the first exon and adjacent regions inherited from the father. Novel genotype causing 5-ARD is presented. Genetic analysis is useful for the diagnosis and timely gender assignment in patients with 5-ARD. However, final gender assignment is difficult and requires combined medical interventions.

show abstract

“…20 Relevant researches indicate that one in three men aged over 80 years needs treatment to relieve BPH-induced symptoms. 18,19,21,22 Apart from age, multiple factors play certain roles in the occurrence and development of BPH including sex steroid hormone levels and genetic predisposition, [23][24][25][26][27] obesity, free prostate specific antigen (PSA) level, cardiovascular disease (CVD), the use of -blocker medications, 28,29 type 2 diabetes mellitus (DM), 30 and hypertension. 31 Moreover, BPH is also considered as a component of the metabolic syndrome (Mets).…”

Section: Introductionmentioning

confidence: 99%

The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population

Zeng

Liu

Gong

et al. 2018

J Evidence Based Medicine

Self Cite

View full text Add to dashboard Cite

Bladder cancer and benign prostatic hyperplasia have been two very common diseases among the elderly men, especially with the aging of the population in the world. We have designed a study to investigate the clinical effect of interventional therapy for plasmakinetic resection of the prostate and plasmakinetic resection of the bladder, which is called "BPSC" (The bladder cancer and benign prostatic hyperplasia study in Chinese population). The BPSC is not only a specific study, it is made up of many studies. In this article, we introduced the research background, source, name, study framework, study management and further direction of BPSC project. We hope this process will contribute to the growth of the database through sharing data and enriching the evidence of bladder cancer and benign prostatic hyperplasia in the Chinese population, thereby finally improving the accessibility of these important findings for doctors, researchers, and patients.

show abstract

Relationship between SRD5A2 rs9282858 polymorphism and the susceptibility of prostate cancer

Cited by 9 publications

References 40 publications

The association between CCND1 G870A polymorphism and colorectal cancer risk

The association between CCND1 G870A polymorphism and colorectal cancer risk

Novel genotype in two siblings with 5-α-reductase 2 deficiency: Different clinical course due to the time of diagnosis

The BPSC: A prospective study investigating the clinical effect of interventional therapy and the risk factors for bladder cancer and benign prostatic hyperplasia in Chinese population

Contact Info

Product

Resources

About